The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Assessing OBX-115, a novel TIL therapy for melanoma, in the Agni-01 trial
Allison Betof Warner, MD, PhD, Stanford University, Stanford, CA, discusses the rationale and trial design of the Phase II Agni-01 (NCT06060613) cohort in advanced melanoma, highlighting the promising results of the Phase I to II transition for OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) cell therapy. The Phase II registrational intent cohort will involve a single-arm study with 86 patients receiving TIL therapy plus small molecule regulation, building on the 67% objective response rate and favorable toxicity profile observed in the previous study. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
